Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease

doi:10.3748/wjg.v20.i45.16841

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 45

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (12346)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-2) series.

Item

Count

PDF

702

WORD

283

HTML

6265

Tables (1-2)

210

Sum=7460

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

606

Download

1348

Sum=1954

Publishing Process of This Article

Item

Count

Browse

1441

Download

1491

Sum=2932

Dec 7, 2014 (publication date) through Nov 16, 2024

Times Cited of This Article

Times Cited (34)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Dec 7, 2014; 20(45): 16841-16857
Published online Dec 7, 2014. doi: 10.3748/wjg.v20.i45.16841

Table 1 Main treatments and emerging drugs for patients with non-alcoholic fatty liver disease

Lifestyle intervention	Anti-obesity drugs	Glucose control	Lipid-lowering drugs	Cytoprotectiveagents	Other drugs	Emerging drugs and new horizons
Diet	Orlistat	Insulin-sensitizing agents	Statins, fibrate and ezetimibe	Ursodeoxycholic acid	Probiotics	Inhibitors of caspases
Weight loss	Cannabinoid agonists	New anti-diabetic drugs	Probucol	Anti-oxidants	Anti-TNF-α monoclonal antibodies	Adenosine system drugs
Physical exercise		Renal glucose transporters blockers		Herbal products	Anti-hypertensive drugs	PPAR agonists
Surgery (not treated)					Pentoxifylline	Peripheral cannabinoid agonists
					Iron depletion	Farnesoid X receptor agonists
						Thyroid hormone analogues

TNF: Tumor necrosis factor; PPAR: Peroxisome proliferator-activated receptors.

Citation: Federico A, Zulli C, de Sio I, Del Prete A, Dallio M, Masarone M, Loguercio C. Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20(45): 16841-16857
URL: https://www.wjgnet.com/1007-9327/full/v20/i45/16841.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i45.16841